All

Digital Technologies Department of Seventure Partners announces CONJECT Holding GmbH acquisition by ACONEX Ltd.
17 March 2016

Digital Technologies Department of Seventure Partners announces CONJECT Holding GmbH acquisition by ACONEX Ltd.

The Digital Technologies Department of Seventure Partners, leading venture capital firm in Europe for innovation funding, today announces the selling of CONJECT Holding GmbH, a...

Read the press release
payleven successfully closes USD 10 million Series D growth financing round and expands investor portfolio
11 February 2016

payleven successfully closes USD 10 million Series D growth financing round and expands investor portfolio

payleven, the leading mobile payments company for small and medium sized businesses, announced today the close of its Series D funding round with the addition of Seventure...

Read the press release
Studitemps records a successful 1st half in 2015
10 October 2015

Studitemps records a successful 1st half in 2015

In the first half of 2015, Studitemps (www.studitemps.de), one of Germany‘s leading job placement agencies for students, has been able to double the number of locations in...

Read the press release
Mailjet Raises $11 Million Series B to Expand Marketing and Transactional Email Deliverability
15 July 2015

Mailjet Raises $11 Million Series B to Expand Marketing and Transactional Email Deliverability

Mailjet, the all-in-one email service provider, today announced a $11M Series B funding round, led by Iris Capital, with returning investor Alven Capital and new investor...

Read the press release
Seventure invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma™
9 January 2015

Seventure invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma™

Seventure Partners, one of Europe’s leaders in financing innovation, announces today its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure...

Read the press release
TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
4 December 2014

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...

Read the press release